The 10-Year Cost of Prostate Cancer Radiotherapy: Late Urinary Adverse Effects

ContributorsProf. Dr. Mustafa ÖzdoğanAuthor · Medical review · Editorial approval

PublishedMay 13, 2026

UpdatedOct 16, 2026

4 min read

The 10-Year Cost of Prostate Cancer Radiotherapy: Late Urinary Adverse Effects

In this article

Primary radiotherapy is an established treatment modality with curative intent for localized prostate cancer, strongly supported by the EAU guidelines. However, excellent oncological outcomes — survival and disease control — must not overshadow the reality of treatment-related late genitourinary (GU) toxicity . The study by Dries Develtere and Riccardo Bertolo in the Journal of Clinical Oncology (2026) shows that post-radiation morbidity is often incompletely characterized and that the cumulative burden increases dramatically as follow-up lengthens. This text examines the long-term (10+ years) “toxicity bill” of modern radiotherapy techniques in light of current randomized controlled trials.

— INTRODUCTION: THE TOXICITY PARADOX —

Post-radiation urinary morbidity often manifests clinically months or even years later because of progressive fibrosis and vascular damage induced in the tissues. This “delayed presentation” extends beyond standard follow-up procedures at radiotherapy centers. Comparing complication profiles of surgery and radiotherapy internationally, Wallis et al. (2018) noted that late GU complications of radiotherapy follow a different natural course from those of surgery. Meta-analyses by David et al. (2023) showed that reported long-term toxicity is much higher — particularly at Grade ≥2 — clearly revealing the “early follow-up fallacy” in the literature.

— ANALYSIS OF RANDOMIZED EVIDENCE: PACE-B AND HYPO-RT-PC —

Two recently published pivotal studies have provided groundbreaking findings for standardizing toxicity data and long-term follow-up:

COMPARATIVE SUMMARY OF THE STUDIES

HYPO-RT-PC (10-Year Follow-Up - 2026): Comparing ultra-hypofractionation (42.7 Gy / 7 fr) with conventional fractionation (78 Gy / 39 fr), this study is a milestone in the radiotherapy literature, with outcomes extending to 10 years. The more than twofold increase in cumulative toxicity from year 5 to year 10 has redefined the significance of “late effects” in oncology.
PACE-B (5-Year Follow-Up - 2024): It examined the toxicity profile of SBRT (36.25 Gy / 5 fr) compared with conventional radiotherapy. The toxicity rates detected at year 5 show that even modern radiotherapy carries a risk of serious adverse effects.

30%

HYPO-RT-PC Year 10 Cumulative (Ultra-hypo)

26.9%

PACE-B Year 5 Cumulative (Ultra-hypo)

— REAL-WORLD DATA AND CLINICAL RELEVANCE —

The controlled environment of clinical trials should be supported by “real-world” data. Data from the registry run by Bertolo et al. (2026), IRRADIaTE , shed light on the challenges of managing urinary toxicity after radiotherapy in routine clinical practice. Herr et al. (2023) examined outcomes in patients treated within national health systems and confirmed that controlled-trial data show a similar, and sometimes worse, course in the general population.

An Important Distinction: Cumulative incidence represents the probability that a patient will experience toxicity at any time after treatment (lifetime burden), whereas point prevalence reflects symptoms at that moment. Focusing on point prevalence in patient counseling may lead patients into a false sense of security that “the risk ends when treatment ends.”

⚡ DROZDOGAN ACADEMY — CLINICAL STRATEGY

⚡ WHY DOES IT MATTER?

Although modern radiotherapy (SBRT, ultra-hypo) shortens treatment duration without compromising oncological control, it “has not eliminated toxicity completely.” Long-term data show that the biological nature of radiation damage has not changed.

🩺 IMPLICATIONS FOR CLINICAL PRACTICE

1. Counseling: Patients should be told not about 5-year success, but about the cumulative risk of adverse effects over 10+ years.
2. Follow-Up: Follow-up after radiotherapy should include not only “PSA monitoring” but also “screening for urinary morbidity.”
3. Treatment Choice: When discussing comparisons with radical prostatectomy in younger patients, the risk of “early incontinence” after surgery should be balanced against the risk of “late cumulative urinary morbidity” after radiotherapy.

References

Develtere D, Bertolo R. Cumulative Genitourinary Toxicity After Prostate Radiotherapy: High-Level Long-Term Randomized Evidence. J Clin Oncol. 2026. DOI: 10.1200/JCO-26-00436.
Nilsson P, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 2026;27:293-301.
van As N, et al. Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer (PACE-B). New Engl J Med 2024;391:1413-1425.
Bertolo R, et al. Real-world burden and management of late genitourinary toxicity after prostate radiotherapy: Insights from IRRADIaTE. Eur Urol Oncol 2026.
David R, et al. Long term genitourinary toxicity following curative intent intensity-modulated radiotherapy: A systematic review and meta-analysis. Prostate Cancer Prostatic Dis 2023;26:8-15.
Herr DJ, et al. Outcomes after definitive radiation therapy for localized prostate cancer in a national health care delivery system. Cancer 2023;129:3326-3333.
Wallis CJD, et al. Survival and complications following surgery and radiation for localized prostate cancer: An international collaborative review. Eur Urol 2018;73:11-20.
EAU Guidelines. Prostate Cancer. EAU Guidelines Office, Arnhem. (uroweb.org/guidelines/prostate-cancer).

Note: This content was prepared for clinical decision-makers in oncology on the basis of the cited current academic publications, including data from 2026. The information is for informational purposes only; treatment protocols should be planned for each patient by multidisciplinary boards.

Reader comments

Share your comment

Your name and comment are published only after administrator approval. Your email address is never shown to visitors.

Be the first to comment.

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

Menu